Switch Study of Existing Atypical Antipsychotics to Bifeprunox
NCT00347425
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Males or females, 18-65 years, meeting DSM-IV TR diagnosis of Schizophrenia or Schizoaffective Disorder for whom a switch is indicated
- Acutely psychotic or with a current Axis I primary psychiatric diagnosis other than
schizophrenia or schizoaffective disorder based on DSM-IV TR criteria
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Birmingham, Alabama
- Little Rock, Arkansas
- Anaheim, California
- Cerritos, California
- Cerritos, California
- Culver City, California
- Garden Grove, California
- La Palma, California
- Long Beach, California
- Oceanside, California
- Paramount, California
- Pasadena, California
- Sacramento, California
- San Diego, California
- San Diego, California
- Santa Ana, California
- Torrance, California
- Boca Raton, Florida
- Gainesville, Florida
- Hialeah, Florida
- Jacksonville, Florida
- Miami, Florida
- North Miami, Florida
- North Miami, Florida
- Orange City, Florida
- Orlando, Florida
- Tampa, Florida
- Atlanta, Georgia
- Augusta, Georgia
- Decatur, Georgia
- Chicago, Illinois
- Indianapolis, Indiana
- Lake Charles, Louisiana
- Shreveport, Louisiana
- Glen Burnie, Maryland
- Detroit, Michigan
- Minneapolis, Minnesota
- St. Charles, Missouri
- St. Louis, Missouri
- St. Louis, Missouri
- Clementon, New Jersey
- Kenilworth, New Jersey
- Albuquerque, New Mexico
- Brooklyn, New York
- Cedarhurst, New York
- Jamaica, New York
- New York, New York
- Staten Island, New York
- Chagrin Falls, Ohio
- Cincinnati, Ohio
- Oklahoma City, Oklahoma
- Philadelphia, Pennsylvania
- Philadelphia, Pennsylvania
- Sioux Falls, South Dakota
- Memphis, Tennessee
- Memphis, Tennessee
- Austin, Texas
- Conroe, Texas
- Houston, Texas
- San Antonio, Texas
- Richmond, Virginia
- Spokane, Washington
- Huntington, West Virginia
- Buenos Aires,
- Buenos Aires,
- Cordoba,
- La Plata,
- Mendoza,
- Mendoza,
- Mendoza,
- Rosario,
- Chatham, Ontario
- Mississauga, Ontario
- Calgary,
- Claresholm,
- Halifax,
- Hull,
- Kelowna,
- Kingston,
- Markham,
- Medicine Hat,
- Orleans,
- Ottawa,
- Prince Albert,
- Sherbrooke,
- Victoria,
- Winnipeg,
- Bolonska,
- Jablonova,
- Litomerice,
- Na Markvartce,
- Olomouc,
- Plzen,
- Prague,
- Praha,
- Rejskovo namesti,
- Paldksi Mnt,
- Tartu,
- Voru,
- Clermont Ferrand,
- Dole,
- St. Cyr au Mont d Or,
- Balassagyarmat,
- Budapest,
- Budapest,
- Budapest,
- Budapest,
- Debrecen,
- Gyor,
- Gyula,
- Pecs,
- Balvi,
- Jelgava,
- Liepaja,
- Riga,
- Sigulda,
- Kaunas,
- Kaunas,
- Klaipeda,
- Silute,
- Vilnius,
- Vilnius,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Switch Study of Existing Atypical Antipsychotics to Bifeprunox | |||
Official Title ICMJE | A Multicenter, Open-Label, Parallel-Group, Randomized, Flexible Dose Study To Evaluate the Safety and Tolerability of Switching From Existing Atypical Antipsychotics to Bifeprunox in Subjects With Schizophrenia or Schizoaffective Disorder | |||
Brief Summary | The study will evaluate the safety and tolerability of switching subjects with schizophrenia or schizoaffective disorder from their existing antipsychotic medication to Bifeprunox. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Schizophrenia and Schizoaffective Disorder | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Actual Enrollment ICMJE | 286 | |||
Original Enrollment ICMJE | Not Provided | |||
Actual Study Completion Date ICMJE | February 2008 | |||
Actual Primary Completion Date | February 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 65 Years (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Argentina, Canada, Czech Republic, Estonia, France, Hungary, Latvia, Lithuania, United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00347425 | |||
Other Study ID Numbers ICMJE | S154.3.020 2006-004972-11 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Loretta Stallings, Solvay Pharmaceuticals | |||
Study Sponsor ICMJE | Solvay Pharmaceuticals | |||
Collaborators ICMJE |
| |||
Investigators ICMJE |
| |||
PRS Account | Solvay Pharmaceuticals | |||
Verification Date | May 2008 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |